Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7) Meeting Abstract
| Authors: | Westin, J.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M.; Perales, M. A.; Farooq, U.; Wannesson, L.; Leslie, L. A.; Kersten, M. J.; Jacobson, C. A.; Pagel, J. M.; Wulf, G.; Du, L.; Snider, J.; To, C. A.; Oluwole, O. O. |
| Abstract Title: | Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302010 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7548 |
| Notes: | Meeting Abstract: 7548 -- Meeting also held virtually -- Source: Wos |
